Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.50 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9752550 | 0.89 | TOP2A (0.47) | TOP2ATOP2BPTGS1LMNACRBN | |
| SCHEMBL5707893 | 0.85 | TOP2A (0.48) | TOP2ATOP2BPTGS1LMNACRBN | |
| SCHEMBL29130872 | 0.85 | PTGS1 (0.44) | TOP2ATOP2BPTGS1LMNACRBN | |
| SCHEMBL11383117 | 0.81 | PTGS1 (0.46) | TOP2ATOP2BPTGS1LMNACRBN | |
| SCHEMBL31377154 | 0.79 | APEX1 (0.42) | TOP2ATOP2BPTGS1LMNACRBN | |
| SCHEMBL11023978 | 0.79 | ALDH1A1 (0.47) | TOP2ATOP2BPTGS1LMNACRBN | |
| SCHEMBL1101973 | 0.79 | — | — | |
| SCHEMBL16349791 | 0.78 | TOP2A (0.52) | TOP2ATOP2BPTGS1LMNACRBN | |
| SCHEMBL15548784 | 0.78 | TOP2A (0.47) | TOP2ATOP2BPTGS1LMNACRBN | |
| Ethane SCHEMBL27676633 | 0.77 | CRBN (0.55) | TOP2ATOP2BPTGS1LMNACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011524851-A | — | — | 2011-09-08 | — | — | JP | claimed |
| EP-2242360-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | Tosk, Inc. (US) | 2010-10-27 | — | — | EP | claimed |
| WO-2009102808-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK, INCORPORATED (US) | 2009-08-20 | — | — | WO | claimed |
| JP-62135472-A | — | — | None | — | — | JP | disclosed |
| JP-60097963-A | — | — | None | — | — | JP | disclosed |
| US-20230233501-A1 | COMPOSITIONS FOR INHIBITING 3' REPAIR EXONUCLEASE 2 AND METHODS OF SCREENING FOR SUCH COMPOSITIONS | UNIV TEXAS (US) | 2023-07-27 | — | — | US | disclosed |
| US-11612580-B2 | Compositions for inhibiting 3′ repair exonuclease 2 and methods of screening for such compositions | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-03-28 | — | — | US | disclosed |
| US-9616051-B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616051-B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9468613-B2 | Doxorubicin adjuvants to reduce toxicity and methods for using the same | TOSK, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150258046-A1 | Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same | TOSK, INC. | 2015-09-17 | — | — | US | disclosed |
| JP-S62135472-A | NOVEL 1,2-BIS-3,5-DIOXOPIPERAZINYLETHANE DERIVATIVE | YAKULT HONSHA CO LTD | 1987-06-18 | — | — | JP | disclosed |
| US-4650799-A | Bis-dioxopiperazine derivatives, process for their preparation, antitumor agents comprising them and compositions containing them | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-03-17 | — | — | US | disclosed |
| EP-0197752-A2 | Pharmaceutical compositions | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-10-15 | — | — | EP | disclosed |
| JP-S6097963-A | BIS-DIOXOPIPERAZINE DERIVATIVE, ITS PRODUCTION AND ANTITUMOR AGENT COMPOSED THEREOF | ZENYAKU KOGYO KK | 1985-05-31 | — | — | JP | disclosed |
| EP-0140327-A2 | Bis-dioxopiperazine derivatives, process for their preparation, antitumor agents comprising them and compositions containing them | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-05-08 | — | — | EP | disclosed |
| EP-0125475-A1 | Bis-dioxopiperazine derivatives, process for their preparation, antitumor agents comprising them and compositions containing them | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1984-11-21 | — | — | EP | disclosed |
| US-4404381-A | Novel 3,5-diketo-piperazinyl compounds containing epoxide substituted imides | THE DOW CHEMICAL COMPANY (US) | 1983-09-13 | — | — | US | disclosed |
| US-4275063-A | 1,2-BIS(3,5-DIOXOPIPERAZIN-YL)PROPANE FOR TREATMENT OF CANCER IN HUMANS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1981-06-23 | — | — | US | disclosed |
| JP-S0697963-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258046-A1 | Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same | TOP2A, TLR5, MYD88 | TOP2A 1/4885TOP2B 5/4885PTGS1 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.